Polymer Capital Management’s Blueprint Medicines BPMC Stock Holding History

Polymer Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,544	Closed	-$454K	–	774
2025 Q2	$454K	Buy	+3,544	New	+$368K	0.05%	279

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Polymer Capital Management's BPMC Position: Q3 2025 in Review

Polymer Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 3,544 shares — an estimated $454K sold.

Polymer Capital Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $454K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Polymer Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Polymer Capital Management sold 3,544 Blueprint Medicines shares in Q3 2025, an estimated $454K.
Polymer Capital Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Polymer Capital Management's Blueprint Medicines position peaked at $454K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Polymer Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.